NOX
Delivery · Highdata caveat$26MCF+
Noxopharm
Biotechnology · Oncology
Senolytic and anti-inflammatory oncology pipeline
Data HealthTrials1 of 1 active · stale enrollment
Cash data from Mar 2026 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$0.9M
Mar 2026 4C
Runway
CF+Cash Flow Positive
Based on Mar 2026 4C
Market Cap
$26M
Burn Rate
—
Mar 2026 4C
Shares Outstanding
309M
Pipeline Assets
3
Latest Insightprice-sensitive announcements & broker notes
Price-sensitiveOther8 June 2026
SOF-SKN manufacturing begins to ensure clinical trial readi
Noxopharm has commenced manufacturing of SOF-SKN for a planned clinical trial later in 2026, with the process expected to take several weeks including quality control checks. The company is investigating prospects for a pilot study in cutaneous lupus erythematosus (CLE), a chronic autoimmune inflammatory disease with a global market worth over US$3.3 billion.
3M Price
NOX.ASX$0.085+44.1% 3M
Low $0.058High $0.089
Pipeline Assets (3)
Capital Raises & Buybacks
12mo dilution 0.6%12mo $0.1M1 raise
Current shares outstanding: 309M
Other
2026-05-08other
$0.1M
Other ticker dataInsider activity, holders, grants, publications
expand ›
Insider activity, holders, grants, publications
Director Transactions
1 transactionLast 90dNet Sell
Buys0
Sells1+1 vs prior
Sell Value$38k
Catalysts (12)· 0 upcoming · 12 past
expand_more12 past catalysts
ConfirmedremoveMed8 June 2026
Noxopharm has commenced manufacturing of SOF-SKN for a planned clinical trial later in 2026, with the process expected to take several weeks including quality control checks. The company is investigating prospects for a pilot study in cutaneous lupus erythematosus (CLE), a chronic autoimmune inflammatory disease with a global market worth over US$3.3 billion.
Confirmed
Track RecordDelivery Consistency Index
expand ›
Delivery Consistency Index
Historical delivery and spending consistency. Data is limited for recently added companies.
Delivery Consistency Index
Delivery
High83/100(limited data)
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
High93/100(limited data)
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Hit 4 of 4 guided dates· rolling 2yr· of 12 tracked
Filed 1 of 1 4Cs on time· statutory deadline· 1 filing without matched announcement
What drove these scores · rolling 2yr
arrow_drop_up
Cash-flow positive — 1/2 quarters with positive operating cash flow
arrow_drop_up
Cash position improving — Cash balance growing
·
SOF-SKN™ FDA — Noxopharm progresses US regulatory strategy — Delivered on time
·
Proposed issue of securities - NOX — Delivered on time
·
New data confirms cancer-fighting potential — Delivered on time
·
SOF-SKN manufacturing begins to ensure clinical trial readi — Delivered on time
·
Limited data adjustment — Score adjusted toward neutral (4/6 data points) — accuracy improves with more completed catalysts
Completed catalysts
✓SOF-SKN™ FDA — Noxopharm progresses US regulatory strategy— Noxopharm is preparing for a pre-IND meeting with the US FDA for SOF-SKN™, a drug candidate for chronic inflammation caused by cutaneous lupus erythematosus, having engaged CRO Novotech to support the data package preparation. This pre-IND meeting is a precursor step toward a full IND application submission in the US.
On time
✓Proposed issue of securities - NOX
On time
✓New data confirms cancer-fighting potential— Noxopharm has demonstrated that its Sofra technology platform can significantly amplify TLR8 immune activation for cancer treatment, with oligonucleotides showing >200-fold enhancement in human skin biopsies and ~3-fold increases in animal models. The company is advancing development toward humanized mouse and cancer model testing, positioning the platform as a potential competitive addition to the immuno-oncology market projected to reach US$185 billion by 2035.
On time
✓SOF-SKN manufacturing begins to ensure clinical trial readi— Noxopharm has commenced manufacturing of SOF-SKN for a planned clinical trial later in 2026, with the process expected to take several weeks including quality control checks. The company is investigating prospects for a pilot study in cutaneous lupus erythematosus (CLE), a chronic autoimmune inflammatory disease with a global market worth over US$3.3 billion.
On time
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Clinical Trials(1)
1 activeClinicalTrials.gov ↗
Early Ph1RecruitingEnrollment stale · 331d
SOF-SKN 0.25%SOF-SKN 0.5%SOF-SKN 1%
Clinical Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of SOF-SKN in Healthy Participants
Cutaneous Lupus Erythematosus
RandomizedQuadruple Blind18 Years – 64 Years
Primary endpoint Percentage of Target Toxicities after a single treatment
ENROL32
no manual snapshots — enter via record_enrollment.py
Announcements(19)
article
OtherPSauto_awesome
SOF-SKN manufacturing begins to ensure clinical trial readi8 June 2026
expand_more361KB
description
19 May 2026
358KB